Colibri Heart Valve Receives European Patent for a Method of Making a Pre-packaged, Sterilized Dry Heart Valve, Pre-mounted on a Delivery Catheter

Wednesday, April 27, 2016

BROOMFIELD, CO – April 27, 2016 – Colibri Heart Valve LLC, a privately held emerging medical device company, has received notification from the European Patent Office that patent application No. 11751242.6 titled, “Percutaneously Deliverable Heart Valve and Methods Associated Therewith” has been granted and is expected to publish as European Patent No. 2542184 (the “European Patent”) on May 25, 2016. This European Patent is directed towards a method of making a pre-packaged, sterilized dry heart valve mounted on a delivery catheter and has priority claims dating back to March 1, 2010. This European Patent is a significant addition to Colibri’s intellectual property (IP) portfolio in the field of a pre-packaged ready-for-use transcatheter heart valve (THV) mounted on a delivery system, and represents the 15th Colibri patent allowed/granted to date.

Colorado BioScience Association taps executives from leading life science organizations to join board of directors

Friday, April 22, 2016

Five new board members represent Biodesix, Dohmen Life Science Services, CU-Boulder, SomaLogic and Clovis Oncology 
Continue Reading

ArcherDX Launches NGS Assays for Hematological Malignancy Profiling April 18th, 2016 08:41 AM Eastern Daylight Time

Monday, April 18, 2016

BOULDER, Colo.—ArcherDX, Inc., announced three new targeted next generation sequencing assays to capture and identify known and novel gene fusions, point mutations and relative expression levels in myeloid and lymphoid origin malignancies. The new Archer™ FusionPlex™ Blood Cancer panels utilize Archer’s proprietary Anchored Multiplex PCR (AMP™) to detect known and novel fusions from RNA. AMP also tags each input fragment with a barcode for molecular quantification for expression level detection and added confidence in mutation detection. Archer FusionPlex Heme v2, Myeloid and ALL panels each interrogate 80-90 genes, simultaneously detecting fusions, critical point mutations and expression levels when analyzed using the Archer Analysis bioinformatics platform.

“We designed these blood cancer panels to target and detect all types of driver mutation events, so that clinical researchers have the most information possible about a tumor sample,” said Brian Kudlow, Ph.D., VP of Research and Development at ArcherDX. “Gene fusions are a particularly important class of mutations in hematological malignancies. For example, Ph-like ALL fusions are critical markers for pediatric acute lymphoblastic leukemia; yet, existing methods struggle to detect and provide answers in a timely and multiplex fashion.”

The assays are the newest additions to the FusionPlex product line, which includes panels for sarcoma and solid tumor mutation profiling.

About ArcherDX


ArcherDXaddresses the bottlenecks associated with using NGS in translational researchby offeringa robust platform for targeted sequencing applications.


By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use,lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries todetect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite ofbioinformatics software,ArcherDXtechnology dramatically enhances complex mutationidentification and discovery.


ArcherDXis headquartered in Boulder, Colorado.


Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.



ArcherDX, Inc.

Jason Amsbaugh

+1 303 357 9001

Continue Reading

C-Span devotes entire morning to Centers for Disease Control and Prevention

Monday, April 11, 2016

This morning, C-Span’s Washington Journal – a three hour national public affairs morning call-in show – devoted its entire show to the Centers for Disease Control and Prevention (CDC). 

Aytu BioScience Demonstrates Clinical Utility of MiOXSYS for Measuring Oxidative Stress Levels in Semen as a Marker for Male Infertility at American Society of Andrology 41st Annual Meeting in New Orleans

Tuesday, April 05, 2016

Englewood, CO – April 5, 2016 – Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, observed encouraging data from two prospective studies of its MiOXSYS™ System that demonstrated its clinical utility as a tool for measuring oxidation-reduction potential (ORP) to assess the degree of oxidative stress levels in human semen. Such oxidative stress is broadly implicated as a major cause of male infertility. The results were presented on April 3rd and 4th at the 41st American Society of Andrology (ASA) annual meeting in New Orleans, Louisiana. 

Early Clinical Evidence Shows Surefire Technology Achieves 80% Complete Tumor Response, Effective in Downstaging Patients to Transplant

Monday, April 04, 2016

Study presented at SIR Evaluated Efficacy of Surefire Technology in Treatment of Primary Liver Cancer 
Continue Reading

Surefire Medical Launches New Precision Device with Increased Length and 1200 PSI Rating

Sunday, April 03, 2016

New device provides for additional access in patient procedures, improved imagery 
Continue Reading

Colorado BioScience Association, Senator Michael Bennet Host U.S. Food and Drug Administration Commissioner Dr. Robert Califf for Life Science Industry Roundtable

Friday, April 01, 2016

Colorado life science leaders cover user fees, regulatory landscape for diagnostics and FDA’s approach to innovative therapies and technologies with the agency’s new Commissioner 
Continue Reading